Why the study?
Oral anticoagulation is indicated for patients undergoing TAVR with concomitant or new-onset AF, but the optimal anticoagulation regimen in this population remained unclear.
Do direct oral anticoagulants (DOACs) reduce all-cause stroke or systemic embolic events compared to vitamin K antagonists (VKA) in patients with atrial fibrillation undergoing transcatheter aortic valve replacement (TAVR)?
Meta-Analysis (n=3,694)
Do direct oral anticoagulants (DOACs) reduce all-cause stroke or systemic embolic events compared to vitamin K antagonists (VKA) in patients with atrial fibrillation undergoing transcatheter aortic valve replacement (TAVR)?
Answers are grounded in this paper and cite their sources.
In patients with atrial fibrillation undergoing TAVR, DOACs demonstrate similar efficacy (stroke/systemic embolism) and safety (major bleeding and all-cause mortality) compared to vitamin K antagonists.
Background Oral anticoagulation therapy is indicated for patients undergoing transcatheter aortic valve replacement (TAVR) with concomitant or new onset atrial fibrillation (AF). However the data on optimal anticoagulation regimen in this population remains unclear. Purpose To compare efficacy and safety outcomes of direct oral anticoagulants (DOACs) versus Vitamin K antagonists (VKA) in patients with AF post TAVR. Methods We searched electronic databases (PubMed, Embase, Scopus, Cochrane) from inception to February28th, 2022 using MeSH terms and keywords for DOACs, AF or TAVR. Primary outcome of interest was all-cause stroke or systemic embolic event. Secondary safety outcomes were major bleeding and all-cause mortality. Pooled risk ratio (RR) and 95% confidence interval (CI) were calculated using a random-effects model. Interstudy heterogeneity was assessed using the Higgins I 2 value. All statistical analysis were performed using RevMan 5.4.1 software. Results We identified five eligible studies (1RCT, 4 observational) including 3694 patients (DOAC n=1581, VKA n=2113). The mean age was 81.4±0.9 years. The mean follow-up was 12.4±14.3 months. Type of DOACs included apixaban (n=394, 24.9%), rivaroxaban (n=354, 22.4%), dabigatran (n=119, 7.5%) and edoxaban (n=714, 45.2%).There was no significant difference in primary outcome of stroke or systemic embolic event (RR: 0.93; CI: 0.65–1.33; p>0.05; I2=5%), or in secondary outcomes of major bleeding (RR: 1.02; CI: 0.78–1.34; p>0.05; I2=44%) and all-cause mortality (RR: 0.87; CI: 0.59–1.27; p>0.05; I2=56%) between DOACs and VKA groups. Conclusion This meta-analysis shows anticoagulation therapy with DOACs has similar safety and efficacy outcomes compared to VKA in patients with AF undergoing TAVR.
No takes yet. Share an insight, caveat, or question.
Dhaliwal et al. (2022) conducted a meta-analysis in Atrial fibrillation after transcatheter aortic valve replacement (TAVR) (n=3,694). Direct oral anticoagulants (apixaban, rivaroxaban, dabigatran, edoxaban) vs. Vitamin K antagonists (VKA) was evaluated on All-cause stroke or systemic embolic event (RR 0.93, 95% CI 0.65-1.33, p=>0.05).
Synapse has enriched 10 related papers. Consider them for comparative context: